PipelineReview.com14h
FDA approves Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease, expanding its use to the second major type of inflammatory bowel disease
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year ...
kffhealthnews1d
FTC Finds Top Three PBMs Took In Billions From Inflated Drug Costs
During a roughly five-year span, CVS Health, Cigna, and UnitedHealth benefited the most from increasing prices for generic drugs that treated illnesses such as HIV and cancer. Some of the price hikes ...
Barchart on MSN2d
Stocks Settle Mixed Ahead of Wednesday’s US CPI Report
Tuesday closed up +0.11%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.52%, and the Nasdaq 100 Index ($IUXX) ...
Pharmaceutical Technology2d
Eisai and Biogen’s subcutaneous Leqembi set for FDA review
Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration (FDA) ...
조선일보5d
Eli Lilly partners with VC to launch 700 billion won biotech ecosystem fund
Eli Lilly partners with VC to launch 700 billion won biotech ecosystem fund Eli Lilly collaborates with a16z to create a vast ...